CompletedNot Applicable

UI-EWD for Endoscopic Hemostasis of Bleeding Peptic Ulcers and Bleeding After EMR/ESD

South Korea76 participantsStarted 2016-05-23

Plain-language summary

UI-EWD (NextBiomedical Co, Incheon, South Korea), a new hemostatic powder for endoscopic treatment of high-risk bleeding peptic ulcers and bleeding after ESD/EMR.

Who can participate

Age range20 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Clinical diagnosis of bleeding peptic ulcer and active bleeding after ESD/EMR Exclusion Criteria: * Coagulation disorder (PLT \< 50\*10\^9/L, INR \> 2) * Connot stop taking the antiplatelet drug, NSAID, Anticoagulant drug, and Aspirin during endoscopic treatment and after 72h endoscopy

What they're measuring

Recurrent bleeding rate

Timeframe: 3 days

Trial details

NCT IDNCT02978391

SponsorNext Biomedical Co., Ltd.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2016-11-30

View on ClinicalTrials.gov More Upper Gastrointestinal Bleeding trials